Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Net Income (2020 - 2024)

Historic Net Income for Inhibikase Therapeutics (IKT) over the last 5 years, with Q4 2024 value amounting to -$12.9 million.

  • Inhibikase Therapeutics' Net Income fell 19359.61% to -$12.9 million in Q4 2024 from the same period last year, while for Sep 2025 it was -$12.9 million, marking a year-over-year increase of 3556.25%. This contributed to the annual value of -$28.6 million for FY2024, which is 4230.64% down from last year.
  • As of Q4 2024, Inhibikase Therapeutics' Net Income stood at -$12.9 million, which was down 19359.61% from -$5.8 million recorded in Q3 2024.
  • Inhibikase Therapeutics' 5-year Net Income high stood at -$421869.0 for Q2 2020, and its period low was -$12.9 million during Q4 2024.
  • Over the past 5 years, Inhibikase Therapeutics' median Net Income value was -$4.6 million (recorded in 2022), while the average stood at -$4.2 million.
  • Per our database at Business Quant, Inhibikase Therapeutics' Net Income plummeted by 56674.67% in 2021 and then skyrocketed by 1857.13% in 2024.
  • Over the past 5 years, Inhibikase Therapeutics' Net Income (Quarter) stood at -$1.2 million in 2020, then crashed by 317.36% to -$5.0 million in 2021, then rose by 14.02% to -$4.3 million in 2022, then decreased by 1.58% to -$4.4 million in 2023, then plummeted by 193.6% to -$12.9 million in 2024.
  • Its Net Income was -$12.9 million in Q4 2024, compared to -$5.8 million in Q3 2024 and -$5.1 million in Q2 2024.